OverviewSuggest Edit

ACADIA Pharmaceuticals (formerly known as Receptor Technologies) is a biopharmaceutical company focused on the development and commercialization of medicines that address medical needs in central nervous system (CNS) disorders. Its main product is NUPLAZID that is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The company also works on other solutions for dementia-related psychosis, Rett syndrome, negative symptoms of schizophrenia, etc.

TypePublic
Founded1993
HQSan Diego, CA, US
Websiteacadia-pharm.com
Employee Ratings4.3
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2020)601(+20%)
Job Openings27
Revenue (FY, 2020)$441.8 M(+31%)
Share Price (Nov 2021)$20.6
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ACADIA Pharmaceuticals

Stephen R. Davis

Stephen R. Davis

Chief Executive Officer, Director
Serge Stankovic

Serge Stankovic

President
Austin D. Kim

Austin D. Kim

Executive Vice President, General Counsel and Secretary
Daryl Dekarske

Daryl Dekarske

Senior Vice President, Global Head of Regulatory Affairs and Head of Translational Sciences
Stephanie Fagan

Stephanie Fagan

Senior Vice President Corporate Affairs and Chief Communications Officer
Kathie M. Bishop

Kathie M. Bishop

Senior Vice President, Head of Rare Disease and External Innovation
Show more

ACADIA Pharmaceuticals Office Locations

ACADIA Pharmaceuticals has offices in San Diego and Princeton
San Diego, CA, US (HQ)
12830 El Camino Real #400
Princeton, NJ, US
502 Carnegie Center #300
San Diego, CA, US
3611 Valley Centre Dr Suite 300
Show all (3)

ACADIA Pharmaceuticals Financials and Metrics

ACADIA Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
ACADIA Pharmaceuticals's revenue was reported to be $441.76 m in FY, 2020 which is a 30.3% increase from the previous period.
USD

Revenue (Q1, 2021)

106.6m

Gross profit (Q1, 2021)

101.9m

Gross profit margin (Q1, 2021), %

95.6%

Net income (Q1, 2021)

(66.4m)

EBIT (Q1, 2021)

(66.8m)

Market capitalization (12-Nov-2021)

3.3b

Closing stock price (12-Nov-2021)

20.7

Cash (31-Mar-2021)

304.5m

EV

3.1b
ACADIA Pharmaceuticals's current market capitalization is $3.3 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

223.8m339.1m441.8m

Revenue growth, %

79%52%30%

Cost of goods sold

18.3m19.6m20.6m

Gross profit

205.5m319.5m421.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

63.0m83.2m94.6m90.1m110.1m120.6m106.6m

Cost of goods sold

4.6m5.0m4.7m5.0m5.5m4.8m4.7m

Gross profit

58.4m78.2m89.9m85.1m104.6m115.8m101.9m

Gross profit Margin, %

93%94%95%94%95%96%96%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

134.8m189.7m326.0m

Accounts Receivable

26.1m35.8m48.2m

Prepaid Expenses

20.7m18.6m25.7m

Inventories

4.1m6.3m9.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

97.6m74.4m385.5m173.1m310.4m452.4m304.5m

Accounts Receivable

30.0m31.8m30.8m41.6m43.8m46.3m56.8m

Prepaid Expenses

23.7m18.5m21.4m22.1m24.8m30.0m28.5m

Inventories

4.6m3.8m4.8m6.3m6.2m8.0m10.3m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(245.2m)(235.3m)(281.6m)

Depreciation and Amortization

3.0m2.8m1.5m

Inventories

1.9m(1.7m)(3.3m)

Accounts Payable

(5.6m)4.1m1.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(85.3m)(140.2m)(182.2m)(88.0m)(130.2m)(214.8m)(66.4m)

Depreciation and Amortization

785.0k1.5m2.1m664.0k1.4m2.1m895.0k

Inventories

(557.0k)273.0k(426.0k)(37.0k)(20.0k)(1.7m)(492.0k)

Accounts Payable

108.0k1.5m277.0k(599.0k)(756.0k)(3.8m)356.0k
USDFY, 2018

Revenue/Employee

531.3k

Financial Leverage

1.1 x

P/E Ratio

(8.3)
Show all financial metrics

ACADIA Pharmaceuticals Operating Metrics

FY, 2017FY, 2018FY, 2019FY, 2020

Phase I Trials Products

2

Phase II Trials Products

231

Phase III Trials Products

2232

Registration Phase Products

1
Show all operating metrics

ACADIA Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
CerSci TherapeuticsAugust 24, 2020$52.5 m
ACADIA Pharmaceuticals A/S
ACADIA Pharmaceuticals GmbH
ACADIA Pharma Limited
CerSci Therapeutics Incorporated

ACADIA Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

ACADIA Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

ACADIA Pharmaceuticals Online and Social Media Presence

Embed Graph

ACADIA Pharmaceuticals Company Culture

  • Overall Culture

    C-

    68/100

  • CEO Rating

    B

    77/100

  • Compensation

    C+

    73/100

Learn more on Comparably

ACADIA Pharmaceuticals News and Updates

ACAD SHAREHOLDER DEADLINE TOMORROW: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now

SAN FRANCISCO, June 17, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.

ACAD 11-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Before the June 18th Deadline in Securities Fraud Lawsuit

SAN FRANCISCO, June 07, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.

Should You Buy ACADIA Pharmaceuticals Stock At $22?

We believe that the stock price of ACADIA Pharmaceuticals, a biopharmaceutical company focused on neuroscience drugs, looks undervalued at current levels of around $22. ACAD stock is actually down 37% from levels of around $35 it was at on March 23, 2020, when broader markets made a bottom...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.

Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before June 18, 2021; click here to submit trade information
Show more

ACADIA Pharmaceuticals Blogs

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia Content Import Wed, 12/01/2021 - 09:03 The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of S…

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms

- Yours, Truly Debuts During National Family Caregivers Awareness Month to Encourage the Parkinson’s Disease Community to Preserve and Share Stories and Memories of Their Loved Ones SAN DIEGO --(BUSINESS WIRE)--Nov. 16, 2021-- Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

- 3Q21 net sales of $131.6 million , a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

- Analyses indicate ongoing need for approved treatments with favorable benefit-risk profile for treating patients with dementia-related hallucinations and delusions SAN DIEGO --(BUSINESS WIRE)--Nov. 2, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial Content Import Mon, 11/01/2021 - 16:07 Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial …

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021 Content Import Wed, 10/27/2021 - 09:01 Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021 10/27/21 This release is a backfill f…
Show more

ACADIA Pharmaceuticals Frequently Asked Questions

  • When was ACADIA Pharmaceuticals founded?

    ACADIA Pharmaceuticals was founded in 1993.

  • Who are ACADIA Pharmaceuticals key executives?

    ACADIA Pharmaceuticals's key executives are Stephen R. Davis, Serge Stankovic and Austin D. Kim.

  • How many employees does ACADIA Pharmaceuticals have?

    ACADIA Pharmaceuticals has 601 employees.

  • What is ACADIA Pharmaceuticals revenue?

    Latest ACADIA Pharmaceuticals annual revenue is $441.8 m.

  • What is ACADIA Pharmaceuticals revenue per employee?

    Latest ACADIA Pharmaceuticals revenue per employee is $735 k.

  • Who are ACADIA Pharmaceuticals competitors?

    Competitors of ACADIA Pharmaceuticals include Omeros, Supernus Pharmaceuticals and Alector.

  • Where is ACADIA Pharmaceuticals headquarters?

    ACADIA Pharmaceuticals headquarters is located at 12830 El Camino Real #400, San Diego.

  • Where are ACADIA Pharmaceuticals offices?

    ACADIA Pharmaceuticals has offices in San Diego and Princeton.

  • How many offices does ACADIA Pharmaceuticals have?

    ACADIA Pharmaceuticals has 3 offices.